Mini-Theme: Stories of HTA Impact

Featured in this issue

EDITORIAL
Schulier and Söderholm Werkö: INAHTA stories from the front lines of HTA impact

THEME SUBMISSIONS
Alemán and Pérez Galan: Impact of HTA on judicialization of health rights
Truchon et al.: Shaping quality in Quebec trauma network
Fujita-Rohwerder et al.: Arthroscopy for knee osteoarthritis: Impact of HTA
Ryan et al.: Stakeholder engagement and impact of Irish HTA
Sihvo et al.: Implementing MUMM program
Tivey et al.: Requirements for office-based surgery in Australia

LETTER
Pérez-Cruzado and Cuesta-Vargas: Smartphone reminder in physical activity

METHODS
Mewes et al.: Is "doing more" cost-effective?
García-Pérez et al.: Quality of economic evaluations in trials
Lesen et al.: Ranking of patient benefits of medical devices
Arber et al.: Search filters to identify utility studies

ASSESSMENTS
Ismail et al.: Economic evidence and cancer funding decisions
Chrusciel-Nogalska et al.: Open-source software in dentistry
Gillespie et al.: The OPTI-SCRIPT Study: Economic evaluation
Goerghebeur et al.: Reflective multicriteria to explore HTA values

POLICIES
Turkstra et al.: Effect and reliability of estimated financial impact
Mohtasham et al.: Hospital-based HTA in Iran
Chambers et al.: U.S. payer coverage of panels and sequencing tests
The Journal welcomes submissions of articles that evaluate health technologies to support health policy or practice decisions, or discuss methods of assessing such technologies; please see Journal Aims and Scope for further information. Manuscripts must be reviewed by the Editors and members of the Editorial Board. Those that pass proceed to an international review process, which usually is completed within 4 to 6 weeks. Accepted manuscripts will be published within 4 to 6 months. Articles must be in English. Spelling, capitalization, and punctuation should conform to the 15th Edition of The Chicago Manual of Style (University of Chicago Press).

MANUSCRIPT SUBMISSION AND REVIEW. All manuscript submissions to the International Journal of Technology Assessment in Health Care must be made electronically via ScholarOne Manuscripts, at the website:

http://mc.manuscriptcentral.com/ijtahc

Please follow the detailed instructions on the website to avoid delays. The authors are asked to provide contact information and they may suggest reviewers. The website automatically acknowledges receipt of the manuscript and provides a manuscript reference number. Every effort will be made to provide the author with a rapid review. Correspondence must include manuscript reference number and should be sent by email to the Editorial Office at IJITAH@thl.fi.

PREPARATION OF MANUSCRIPTS. The manuscript, including all references, must be provided in Word or RTF format, double spaced on 8½ × 11 inch scripts. Manuscripts should typically have less than 4,000 words, including the abstract of 250 words maximum, and usually no more than 25 references. Manuscripts should be formatted as follows:

1) cover sheet;
2) an abstract (no more than 150 words);
3) the title page (title, name(s) and affiliation(s));
4) acknowledgments, including source of funding;
5) references;
6) tables with titles, and
7) figures, with captions on a separate page.

The Journal accepts no more than four tables or figures altogether for the published version. Tables and figures exceeding these limits may be posted on the Journal’s website (www.journals.cambridge.org) as supplementary materials. Statistical tables and figures should be numbered sequentially as the tables and figures in the published issue; beginning with Supplementary Table 1 and Supplementary Figure 1. Please use superscript Arabic numerals in parentheses.

Where relevant, manuscripts should include a paragraph on the policy implications of the findings of the study. Acronyms should be clearly spelled out on first use. The use of product trade names should be provided; generic names should be used except where discussion of proprietary brands is essential to the manuscript.

COVER SHEET AND COVER LETTER. A cover letter, signed by all authors, must attest that 1) each author contributed to the conception and design of the study and interpretation of data; 2) the writing of the paper; 3) each author has approved the version being submitted; and 3) the content has not been published nor is being considered for publication elsewhere.

As relevant to the content of the paper, the letter should also attest to the fact that any research with human or animal subjects conforms to the legal and ethical standards of the country in which it was performed. All authors must disclose any financial arrangements with companies whose products are discussed in the paper or their competitors, such information will not be revealed to reviewers but may be included in a suitable format in the final publication if the manuscript is accepted.

Access the Conflict of Interest disclosure form at http://www.icmje.org/coi_instruct.html. The cover letter should also provide all authors full names, professional degrees, and institutional mailing addresses.

In the reference list, do not include material that has been submitted for publication but has not yet been accepted. This material, with its date, should be noted in the text as “unpublished data” as follows: (unpublished data, 2013). See http://www.nlm.nih.gov/bsd/uniform_requirements.html for details.

All tables and figures must have a caption and must be cited in the text. Table footnotes appear directly after the table; table references follow the footnotes. Tables must be submitted in Word or RTF and figures in .tif, .ps, or .eps format.

Authors are responsible for obtaining written permission to publish material for which they do not own the copyright. Contributors will be asked to assign their copyrights to Cambridge University Press.

Open Access. Our standard copyright forms allow Open Access Archiving (for instance posting the Accepted Manuscript in an Institutional Repository or on a personal webpage). Authors can also choose to publish Open Access (making articles freely available for non-commercial use) in a Large number of our Journals by using Cambridge Open Option. For complete information on all the options available please visit http://journals.cambridge.org/OpenAccess

COPYRIGHT AND PROOFREADING. The publishers reserve the right to copyright and proofread all accepted articles. Page proofs will be sent to the lead author for final review.

Reprints. Reprints may be purchased if ordered at proof stage.
Mini-Theme: Stories of HTA Impact

CONTENTS

Editorial
409  Insights from the front lines: A collection of stories of HTA impact from INAHTA member agencies
   *Tara Schuller and Sophie Söderholm Werkö*

Theme Submissions
411  Impact of Health Technology Assessment in litigation concerning access to high-cost drugs
   *Alicia Aleman and Ana Pérez Galan*
415  Shaping quality through vision, structure, and monitoring of performance and quality indicators: Impact story from the Quebec Trauma Network
   *Catherine Truchon, Lynne Moore, Amina Belcaid, Julien Clément, Nathalie Trudelle, Marie-Andrée Ulysse, Benoît Grolleau, Jacinthe Clusiau, Danielle Lévesque and Michèle de Guise*
420  Arthroscopic surgery for knee osteoarthritis: Impact of Health Technology Assessment in Germany
   *Naomi Fujita-Rohwerder, Alric Rüther and Stefan Sauerland*
424  Contribution of stakeholder engagement to the impact of a Health Technology Assessment: An Irish case study
   *Máirín Ryan, Patrick S. Moran, Patricia Harrington, Linda Murphy, Michelle O’Neill, Marty Whelan and Conor Teljeur*
430  Implementing Health Technology Assessment-based recommendations in Finland: Managed uptake of medical methods
   *Sinikka Sihvo, Tuija Ikonen and Marjukka Mäkelä*
434  INAHTA impact story: Legislative and accreditation requirements for office-based surgery in Australia
   *David Tivey, Ning Ma, Joanna Duncan, Yasoba Atukorale, Robyn Lambert and Guy Maddern*

Letter
442  Smartphone reminder for physical activity in people with intellectual disabilities
   *David Pérez-Cruzado and Antonio Ignacio Cuesta-Vargas*

Methods
444  A systematic approach for assessing, in the absence of full evidence, whether multicomponent interventions can be more cost-effective than single component interventions
   *Janne C. Mewes, Lotte M.G. Steuten, Maarten J. Lzerman and Wim H. van Harten*
454  Methodological quality of economic evaluations alongside trials of knee physiotherapy
   *Lidia García-Pérez, Renata Linertová, Alejandro Arvelo-Martín, Carolina Guerra-Marrero, Carlos Enrique Martinez-Alberto, Leticia Cuéllar-Pompa, Antonio Escobar and Pedro Serrano-Aguilar*
463  Exploration and preferential ranking of patient benefits of medical devices: A new and generic instrument for health economic assessments
   *Eva Lesén, Ingela Björholt, Anders Ingelgård and Fredrik J. Olson*
472  Performance of Ovid MEDLINE search filters to identify health state utility studies
   *Mick Arber, Sonia Garcia, Thomas Veale, Mary Edwards, Alison Shaw and Julie M. Glanville*
Assessments

481  Cost-effectiveness impacts cancer care funding decisions in British Columbia, Canada, evidence from 1998 to 2008
    Zahra Ismail, Stuart J. Peacock, Laurel Kovacic and Jeffrey S. Hoch

487  Open-source software in dentistry: A systematic review
    Małgorzata Chruściel-Nogalska, Tomasz Smektała, Marcin Tutak, Katarzyna Sporniak-Tutak and Raphael Olszewski

494  Reducing potentially inappropriate prescribing for older people in primary care: Cost-effectiveness of the OPTI-SCRIPT intervention
    Paddy Gillespie, Barbara Clyne, Adam Raymakers, Tom Fahey, Carmel M. Hughes and Susan M. Smith

504  Exploring values of Health Technology Assessment agencies using reflective multicriteria and rare disease case
    Mireille M. Goetghebeur, Monika Wagner, Dima Samaha, William O’Neil, Danielle Badgley, Hector Castro-Jaramillo,
    Payam Abrishami, Antonio Sarria-Santamera, Irina Cleemput and Michele Tringali

Policies

521  Pharmaceutical benefits advisory committee recommendations in Australia
    Erika Turkstra, Emilie Bettington, Maria L. Donohue and Merehau C. Mervin

529  Hospital-based Health Technology Assessment in Iran
    Farideh Mohtasham, Reza Majdzadeh and Ensiyeh Jamshidi

534  Examining evidence in U.S. payer coverage policies for multi-gene panels and sequencing tests